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Abstract
To assess gene signatures related to humoral response among healthy older
subjects following seasonal influenza vaccination, we studied 94 healthy adults
(50–74 years old) who received one documented dose of licensed trivalent
influenza vaccine containing the A/California/7/2009 (H1N1)-like virus strain.
Influenza-specific antibody (HAI) titer in serum samples and next-generation
sequencing on PBMCs were performed using blood samples collected prior to
(Day 0) and at two timepoints after (Days 3 and 28) vaccination. We identified a
number of uncharacterized genes (ZNF300, NUP1333, KLK1 and others) and
confirmed previous studies demonstrating specific genes/genesets that are
important mediators of host immune responses and that displayed associations
with antibody response to influenza A/H1N1 vaccine. These included interferon-
regulatory transcription factors (IRF1/IRF2/IRF6/IRF7/IRF9), chemokine/chemo-
kine receptors (CCR5/CCR9/CCL5), cytokine/cytokine receptors (IFNG/IL10RA/
TNFRSF1A), protein kinases (MAP2K4/MAPK3), growth factor receptor
(TGFBR1). The identification of gene signatures associated with antibody response
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represents an early stage in the science for which further research is needed. Such
research may assist in the design of better vaccines to facilitate improved defenses
against new influenza virus strains, as well as better understanding the genetic
drivers of immune responses.
Keywords: Genetics, Immunology
1. Introduction
Influenza viruses infect, sicken, and kill humans across the world and across all age
groups, but this is especially true among older adults [1]. Influenza A viruses
(category C bioagents [2]) are single-stranded RNA Orthomyxoviridae viruses,
characterized by specific hemagglutinin and neuraminidase transmembrane
glycoproteins that generate subtype specific immune responses. Influenza A/
H1N1 gained prominence during the pandemic of 1918 when a highly pathogenic
novel H1N1 virus spread across the world, killing an estimated 50 million people
[3]. Since its re-emergence in 1977, A/H1N1 has been included in the seasonal
trivalent inactivated influenza (TIV) and in the inactivated quadrivalent influenza
vaccines.
Greater than 70–90% of healthy adults seroconvert to influenza vaccine [4].
When the vaccine is well matched, TIV is 70–90% protective against laboratory-
confirmed influenza infection and up to 90% protective against hospitalization in
healthy adults age <65 years [5, 6]. Unfortunately, protection against infection
and complications due to influenza by influenza vaccines is incomplete (with
failure rates up to 50–70% in the very young, elderly, and immunocompromised
individuals).
To date, few biological markers (or models) exist that explain the development of
immune responses to influenza vaccine, and/or predict vaccine failure. There is
evidence that host genetic factors impact the response to influenza A/H1N1 virus
infections and immune responses to influenza vaccination [7, 8, 9, 10, 11].
However, a more comprehensive understanding of the cellular and molecular
mechanisms of vaccine immunity is needed [12, 13, 14, 15, 16]. Several studies
have applied systems biology approaches to find molecular signatures of vaccine-
induced immune responses in humans [8, 9, 15, 17, 18, 19]. Utilizing gene-to-
biology and biology-to-gene approaches [20], which we define herein, together
with gene expression from next generation sequencing, we sought to identify
biological markers (genes/genesets) that could explain humoral antibody response
variations following seasonal influenza A/H1N1 vaccine in older adults.
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2. Materials and methods
2.1. Participants
Recruitment of subjects described herein is similar or identical to those published
by us elsewhere [21, 22]. As previously reported, healthy adults who received
2010–2011 seasonal trivalent inactivated influenza vaccine (Fluarix), containing
the A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/
Brisbane/60/2008-like viral strains, were enrolled in the study [22, 23].
Specifically, between August 2010 and October 2010, we enrolled 106 healthy
adults (ages 50 to 74 years), recruitment was designed to obtain a uniform
distribution across the age range. All participants underwent detailed review of
their vaccination history and were in good health during the length of this study.
Study participants were excluded from enrollment if they showed symptoms
consistent with influenza prior to or throughout the study. Blood samples were
collected prior to (Day 0, the baseline level of immune status) and after vaccination
(Days 3, the innate immune response; and 28, the peak of serum antibody
response). The Mayo Clinic Institutional Review Board granted approval for the
study. Written, informed consent from all subjects was obtained at the time of
enrollment.
2.2. HAI assay
Our description of the hemagglutination inhibition (HAI) assay is similar to those
we published elsewhere [22, 23]. Serum samples from each subject on Days 0, 3
and 28 visits were used for antibody titer determination. HAI assay was performed
with the influenza A/California/07/2009 (H1N1)-like virus strain, and developed
with 0.6% solution of turkey red blood cells (RBC) [24]. The HAI titer was defined
as the highest dilution of serum that inhibits RBC hemagglutination. Seroconver-
sion to the influenza virus vaccine, as described elsewhere [25], was defined by
either a four-fold increase in the antibody titers between the pre-vaccination and
the serum samples at Day 28, or an increase of antibody titers from <10 to ≥40 for
pre-vaccination and the Day 28 serum samples.
2.3. Next generation sequencing
The mRNA next generation sequencing methods are similar or identical to those
published for our previous transcriptomics studies [26, 27]. In brief, total RNA was
extracted from each sample of cryopreserved mixed PBMCs using RNeasy Plus
mini Kit (Qiagen) and RNAprotect reagent (Qiagen; Valencia, CA). RNA quantity
and quality were assessed by Nanodrop (Thermo Fisher Scientific, Wilmington,
DE) and Agilent 2010 Bioanalyzer (Agilent; Palo Alto, CA), respectively. Full-
length cDNA libraries were created in the Mayo Clinic’s Advanced Genomics
Technology Center, Gene Sequencing Facility using the mRNA-Seq 8 Sample
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Prep Kit (Illumina; San Diego, CA) according to the manufacturer’s protocols.
Poly-A RNA was isolated using magnetic purification with olido-dT coated beads,
fragmented, reverse transcribed into cDNA, and combined with Illumina adaptor
sequences. Library validation and quantification was carried out using DNA 1000
Nano Chip kits on an Agilent 2100 Bioanalyzer (Agilent). cDNA libraries (5–7pM)
were loaded onto individual flow cell lanes and single-end read sequencing was
performed using the Illumin HiSeq 2000 (Illumina) with Illumina’s Single Read
Cluster Generation kit (v2) and 50 Cycle Illumina Sequncing Kit (v3). The
sequencing reads were aligned to the human genome build 37.1 using TopHat
(1.3.3) and Bowtie (0.12.7). HTSeq (0.5.3p3) was used to perform gene counting
while BEDTools (2.7.1) was used to count the reads mapping to individual exons
[28, 29, 30].
2.4. Statistical methods
Total number of counts per gene were obtained from the mRNA expression and
used in all analyses. Quality control was assessed pre- and post-normalization
graphically with minus- vs-average and box-and-whisker plots. The GC content
and gene length adjustments were also evaluated graphically. Normalization of the
gene counts was done with Conditional Quantile Normalization, which accounts
for differences in library size and also adjusts for GC content and gene length [31].
These normalized values were used for subsequent analyses.
Our gene-to-biology analyses utilize per-gene analyses to understand the
relationship of gene expression with vaccine response. Due to the overall goal
of developing multivariable models of dichotomized vaccine response, the logistic
modeling framework was utilized. Specifically, per-gene logistic regression
models were fit with HAI response relative to non-response as the dependent
variable, and the normalized gene count as the independent variable on the log2
scale. These models were fit for each timepoint (Days 0, 3 and 28) and for the
differences in log2 normalized gene counts between timepoints (e.g., Day 3-Day 0,
Day 28-Day 0, and Day 28-Day 3). Evaluation of these timepoints allows us to
address baseline, innate and adaptive humoral gene expression associated with
response, as well as potentially identifying changes in gene expression as they
relate to HAI response (or non-response). Results are presented as odds ratios (OR)
for the 75th percentile relative to the 25th percentile of the gene expression value.
Genes that are described as upregulated are those genes that have a higher
expression level on average in the subjects who responded relative to those who
did not respond to vaccine (as measured by a four-fold increase in the HAI titers
from Day 0 to 28). Likewise, genes that are downregulated are those genes that
have lower expression levels in subjects who responded relative to those who did
not respond.
Article No~e00098
4 http://dx.doi.org/10.1016/j.heliyon.2016.e00098
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Our biology-to-gene analyses utilize a priori known biological information in the
form of genesets in order to maximize power and minimize false discovery.
Specifically, we utilized defined genesets to group genes into putative functional
groups for analyses. Genesets utilized for the biology-to-gene analyses are the
genesets (MSigDB) with significant changes over time (Day 0, Day 3, Day 28)
[32]. Negative binomial generalized estimating equation models were used to
assess changes in gene expression over time, utilizing moderated over-dispersion
parameter estimates from edgeR [33, 34, 35, 36]. These p-values were then
combined for all genes within a geneset utilizing the gamma method of combining
p-values, a self-contained geneset testing method shown to have greater power than
Fisher’s method of combining p-values [20, 37]. Redundancy analysis [38] was
used to reduce the number of genes considered within each geneset model; genes
were excluded from further considerations if the R2 for the gene was greater than
0.75 when modeled as a function of the other genes from the geneset. The
remaining genes from each of these genesets were then included in elastic net
penalized logistic regression models (α = 0.5 and 0.8) of HAI response relative to
non-response as the dependent variable [39]. Models were fit using the “glmnet”
function in R [39], and the optimal model selected according to the minimum
misclassification error based on 10-fold cross validation. Results are presented
with misclassification error rates and coefficients from the models.
2.5. Gene regulatory interactions
We consulted databases of known regulatory interactions to further understand the
biologic relationships linking the genesets that are individually informative for
HAI response. The result is a regulatory network within which differential
expression patterns inform HAI response. To link genesets together and generate
this network, we combined NCI-Nature pathways [40], the Transcription Factor
Encyclopedia [41], and a directed protein interaction network [42], where edge
direction indicates passage of a signal (e.g., protein interaction leading to
phosphorylation). This focuses the analysis on regulatory interactions that should
be robust to subject-specific details.
Using this network, we computed a geneset interaction metric, quantifying the extent
to which two genesets can be directly regulated by each other. For genesets s1 ¼
fg11; g12; : : : ; g1ng and s2 ¼ fg21; g22; : : : ; g2mg that contain ∥s1∥ ¼ n and ∥s2∥ ¼
m genes, let the neighbors of a gene, those adjacent to the gene in a pathway, be
A ðgÞ . Further, let the neighbors of set s1 that are also members of s2 be denoted
A s1
 2 and U the unique set union. Finally, let the unique overlap between the
two sets then be: O s1; s2
  ¼ U A s1 2;A s2 1
 
. Then the interconnectivity is
formally defined as: G ¼ ∥O s1; s2 ∥=∥U s1; s2 ∥ .
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3. Results
3.1. Subject demographics
During the HAI testing, 106 subjects were assayed for HAI titer, and 12 subjects were
excluded: 11 individuals based on influenza virus vaccine serology (i.e., due to a
ceiling titer of 1:640 for which no subject augmented their titer fromDay 0 to Day 28)
[43]; and one subject based on cDNA library preparation failure. Thus, 94 of 106
participants were used in the study. Thirty-six of the 94 vaccine recipients (38.3%)
had at least a four-fold increase in HAI titer to influenza A/H1N1. Demographic data
and other characteristics of these subjects are shown in Table 1. Baseline (Day 0)
influenza-specific HAI titer (median titer of 1:80; IQR 1:40; 1:160) demonstrated the
presence of pre-existing HAI antibodies. Median HAI titer for the entire cohort
increased by Day 28 (median titer of 1:320; IQR 1:80; 1:320, p< 0.001). Comparing
the median HAI titer values between responders (n = 36) and non-responders (n =
58), responders had a lower baseline titer compared to non-responders (p = 0.003)
(Table 1). Pre-existing immunity, as measured by HAI titers at baseline, had a strong
positive correlation with Day 28 titers for subjects classified as responders (r = 0.758,
p = 8.62 × 10−8) and for those classified as non-responders (r = 0.900, p = 7.72 ×
10−22). The change in HAI titer from baseline to Day 28 is illustrated in Fig. 1.
Table 1. Demographic and immunological variables of the study subjects.
Variable Non-responders
(N = 58)
Respondersa
(N = 36)
Overall
(N = 94)
Age, years, median (IQRb) 59.7 (55.9; 69.0) 59.7 (55.0; 63.8) 59.7 (55.4; 67.0)
Gender
(n, %)
Female 37 (63.8) 20 (55.6) 57 (60.6)
Male 21 (36.2) 16 (44.4) 37 (39.4)
Race
(n, %)
Caucasians 57 (98.3) 36 (100.0) 93 (98.9)
Others 1 (1.7) 0 (0.0) 1 (1.1)
HAI titer, median
(IQRb)
Day 0 1:160 (1:80, 1:160) 1:80 (1:40, 1:80) 1:80 (1:40, 1:160)
Day 3 1:160 (1:80, 1:160) 1:80 (1:40, 1:160) 1:80 (1:50, 1:160)
Day 28 1:160 (1:80, 1:320) 1:320 (1:280, 1:1280) 1:320 (1:80, 1:320)
a At least four-fold increase in the antibody titers between the pre-vaccination and the Day 28 sample.
bIQR, interquartile range.
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3.2. Gene expression associated with HAI response (gene-to-
biology approach)
Overall transcriptomic expression (14,917 genes with a median count ≥ 32 reads at
least one timepoint were used for all analyses) related to HAI response (defined as
a positive four-fold change in HAI titer between Day 0 and Day 28) was analyzed
at Days 0 (n = 688 genes had p < 0.05), 3 (n = 163 genes, p < 0.05) and 28 (n =
232 genes, p < 0.05). The false discovery rate (FDR) values for these genes were
>0.9; we report herein a brief summary of these findings. A comparison between
responders and non-responders failed to identify differentially expressed genes at
Days 0, 3, and 28 when multiple-testing correlation was applied to the direct
comparison analysis (FDR <0.05). At Day 0, 49 unique genes had a p-value <0.01.
At Days 3 and 28, eight and seventeen genes, respectively, had a p-value <0.01
(Supplemental Table 1). The top genes with a p-value of<0.002 encode for proteins
that play a central role in numerous cellular processes (such as ARHGEF10, MLST8,
SPATA24, and C17orf97), which are likely to be important in immune response.
Changes in gene expression at Day 28 relative to baseline identified 328 genes (p
< 0.05) significantly associated with HAI response. The top 30 genes with
[(Fig._1)TD$FIG]
Fig. 1. Comparison of baseline HAI titer values to Day 28 HAI titer values. Scatterplot of the HAI titer
at Day 28 versus the HAI titer at baseline. The points on the graph are proportional to the number of
individuals with the corresponding titers. The line through the plot is the divide between the responders
and the non-responders and is based on a four-fold change from baseline to Day 28. Subjects above the
line have a 4-fold or greater change and are responders, while the subjects below the line are classified
as non-responders.
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significant (p < 0.01) transcriptional changes encode for numerous proteins that
comprise signal transduction pathways and transcriptional regulators (TGFBR1,
ZNF300, GLIS2), heat shock proteins and activators of dendritic and T cells
(HSPA14), transmembrane and nucleoporin complex glycoproteins (TM9SF3,
NUP133, CD200), members of RAS oncogene and kallikrein families (RAP2A,
KLK1), along with a number of proteins participating in a various physiological
functions (GPRIN1, GPR153, EGLN1) (Fig. 2A). The majority of these
differentially expressed genes were upregulated. In addition, changes in gene
expression related to HAI response from Day 28 minus Day 3 and from Day 3
minus Day 0 identified 118 (p < 0.05) and 188 (p < 0.05) genes, respectively.
Further, Fig. 2B and C show the results for the genes differentially expressed from
Day 28 minus Day 3, p < 0.01; and the six genes differentially expressed from Day
3 minus Day 0, p < 0.01, respectively. These genes included calcium binding
protein A5 (S100A5), putative RNA helicase (DDX28), zinc finger protein 565
(ZNF565), a regulator of NF-kappa-B-mediated transcription (TONSL), nucleo-
porin protein (NUP133), and other genes with unknown function.
3.3. Geneset signatures associated with HAI response (biology-
to-gene approach)
Our goal was to build multivariable regression models that explain variation in HAI
response. When all genes were used to build multivariable models of HAI response,
no genes entered the model, regardless of whether the Day 0, Day 28, or Day 28–Day
0 delta were used.We reasoned that pathways having statistically significant changes
over time would most likely contain those genes changing in response to vaccine.
Thus, genesets that were previously identified as having significant changes over time
in our mRNA expression data (p < 0.001, FDR < 0.05) were used in models to
predict HAI response (unpublished data). There were a total of 339 genesets for which
models were generated. Thirteen genesets exhibited the ability to explain the odds of
HAI response with models containing genes achieving a cross-validated error rate
<35%. Many of the genes encompassing these 13 genesets have various and/or
unidentified functions (Table 2); however, several genesets were related to immune
functions (TGFBR1, CCR5, CCR9, ADAR, IRFs, CCL5, BAX, MAP2K4, MAPK3,
NSMAF), including production of antibodies (IFNG, IL10RA, TNFRSF1A) (Fig. 3
and Fig. 4). For example, interferon regulatory factor 1 (IRF) and IRF7 genes
function as transcriptional activators of type I IFN genes (α and β) and were found to
be significantly upregulated in relation to theHAI response, and IRF2, IRF6 and IRF9
genes were found to be downregulated (Fig. 4). Interestingly, when the models were
used to classify the glass ceiling subjects (i.e., due to a ceiling titer of 1:640), nine of
the 11 subjects were classified as non-responders.
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[(Fig._2)TD$FIG]
Fig. 2. Univariate HAI response. Forest plots displaying the odds ratios and confidence intervals for the genes with p < 0.01 from univariate logistic regression models with positive HAI response
as the dependent variable. Odds ratios represent the change in odds of a positive HAI response as a result of moving from the 25th percentile to the 75th percentile of the gene expression. The
vertical dashed line corresponds to an odds ratio of 1.0. In panel A, the change in gene expression between days 0 and 28 (Day 28 minus Day 0 delta) is the independent variable. Similarly, panel B
shows results for (Day 28 minus Day 3) delta models, and panel C shows results for (Day 3 minus Day 0) delta models.
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Table 2. Top 13 genesets with minimum cross validated error rate <0.35 in penalized regression models of
HAI response.
Geneset Name [32] Delta α Genes Standardized
Coefficients
Minimum
CV Error
NOL7: Genes down-regulated in SiHa cells by stable expression of
NOL7
(HASINA_NOL7_TARGETS_DN [62])
Day 28 vs
Day 0
0.8 ANGPT1 -0.023 0.29
TGFBR1 0.628
Purine: Genes involved in Purine salvage
(REACTOME_PURINE_SALVAGE)
Day 28 vs
Day 0
0.5 ADA 0.008 0.32
ADAL -0.08
ADK -0.363
AMPD3 -0.08
HPRT1 0.633
PNP 0.15
Ceramide: Ceramide Signaling Pathway
(BIOCARTA_CERAMIDE_PATHWAY)
Day 28 vs
Day 0
0.8 BAX 0.197 0.33
MAP2K4 -0.538
MAPK3 0.006
NSMAF 0.043
TNFRSF1A 0.443
Kurozumi: Inflammatory cytokines and their receptors modulated in
brain tumors
(KUROZUMI_RESPONSE_TO_ONCOCYTIC_
VIRUS_AND_CYCLIC_RGD [63])
Day 28 vs
Day 0
0.8 CCR5 0.065 0.33
CCR9 -0.198
IFNG 0.317
IL10RA 0.063
SHH: Sonic Hedgehog Pathway
(BIOCARTA_SHH_PATHWAY)
Day 28 vs
Day 0
0.8 DYRK1A 1.108 0.34
DYRK1B -0.098
GLI1 0.102
GLI3 0.099
GSK3B 0.684
PRKACB -0.393
PRKAR1A 0.973
PRKAR2B -0.12
PTCH1 0.41
SMO 0.378
SUFU -0.238
(Continued)
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Table 2. (Continued)
Geneset Name [32] Delta α Genes Standardized
Coefficients
Minimum
CV Error
CM: Genes annotated by the GO term GO:0048475.
(COATED_MEMBRANE)
Day 28 vs
Day 0
0.8 AFTPH 0.035 0.34
AP3S1 0.445
MC: Genes annotated by the GO term GO:0030117
(MEMBRANE_COAT)
Day 28 vs
Day 0
0.8 AFTPH 0.035 0.34
AP3S1 0.445
ERG: Genes down-regulated in prostate cancer samples bearing the
fusion of TMPRSS2 with ERG
(SETLUR_PROSTATE_CANCER_TMPRSS2_
ERG_FUSION_DN [64])
Day 28 vs
Day 0
0.8 ITGAD 0.28 0.34
KLHL21 0.254
MPPED2 -0.102
RAB27A 0.088
AMI: Acute Myocardial Infarction
(BIOCARTA_AMI_PATHWAY)
Day 28 vs
Day 3
0.5 COL4A3 0.124 0.34
F2R 0.444
PLAT -0.044
PROC -0.634
PROS1 0.07
TFPI 0.478
EIF: Eukaryotic protein translation
(BIOCARTA_EIF_PATHWAY)
Day 28 vs
Day 3
0.8 EEF2 0.168 0.34
EEF2K 0.351
EIF1AX -0.557
EIF2S1 -0.104
EIF2S2 0.027
EIF2S3 -0.303
EIF3A -0.57
EIF4A1 -0.191
EIF4A2 0.056
EIF4E 0.485
EIF4G3 0.35
EPA: Extrinsic Prothrombin Activation Pathway
(BIOCARTA_EXTRINSIC_PATHWAY)
Day 28 vs
Day 3
0.5 F2R 0.417 0.34
F3 0.24
F5 0.006
PROC -0.673
(Continued)
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3.4. Interactions between genesets
In order to better understand the biological processes, we then identified
interrelationships in these 13 genesets (Day 28 minus Day 0 and Day 28 minus
Day 3). We found four genesets (NOL7, CERAMIDE, KUROZUMI, and STING)
Table 2. (Continued)
Geneset Name [32] Delta α Genes Standardized
Coefficients
Minimum
CV Error
PROS1 0.095
TFPI 0.413
STING: Primary innate immune response genes induced in 293T cells
by overexpression of STING (TMEM173)
(ISHIKAWA_STING_SIGNALING [65])
Day 28 vs
Day 3
0.8 ADAR 0.791 0.34
CCL5 0.519
IRF1 0.552
IRF2 -0.609
IRF6 -0.328
IRF7 0.365
IRF9 -0.498
GOLGI: Genes involved in Transport to the Golgi and subsequent
modification
(REACTOME_TRANSPORT_TO_THE_
GOLGI_AND_SUBSEQUENT_MODIFICATION)
Day 28 vs
Day 3
0.8 B4GALT1 0.25 0.34
B4GALT2 0.439
B4GALT4 -0.019
MAN1C1 -0.079
MCFD2 -0.282
MGAT2 -0.699
MGAT3 0.465
MGAT4A -0.698
MGAT4B 0.111
SAR1B 0.087
SEC13 -0.949
SEC23A 0.319
SEC24B -0.504
ST8SIA6 0.286
Results from the top 13 genesets with minimum cross validation error rate <0.35 in the elastic net penalized logistic regression models
of HAI response. The geneset name provides the abbreviation that is used for simplicity in the text, a brief description and geneset
name from the MSigDB [32] and the actual gene. Delta is the time period that geneset was found to significantly change over time; α is
the elastic net penalty for the model; symbol is the gene symbol of genes that remained in each model; coefficients are from the model
at the minimum misclassification error rate and the minimum CV error rate is the observed error rate after 10-fold cross validation.
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that capture the bulk of identified genes and their interactions (Fig. 5). The
interconnectivity (see Methods) within these genesets is unusually high. Randomly
generating 100,000 genesets of the same size and computing their interconnectivi-
ty, we generated a distribution with mean 0.24 and standard deviation 0.06, while
the observed interconnectivity is 0.90, revealing the observed network density to be
highly non-random. These genesets include members of the protein kinase
receptors, MAPK signal cascade, regulators of NFκB, cytokines/cytokine receptors,
chemokines/chemokine receptors, and interferon regulatory transcription factors.
NFκB interacts with IRF1 and IRF2, which regulate expression of CCL5 (C-C
motif ligand 5). CCL5 links the system to multiple C-C motif chemokine receptors,
which in turn interact with more C-C motif ligands. This integrated paradigm
places these diverse signaling processes into a common regulatory model.
4. Discussion
This study focuses on an examination of the genetics influencing variability in
humoral immunity, with the goal of identifying gene signatures and their influence
on the humoral immune response to influenza vaccine. Our primary focus was to
use two balancing analytical approaches to assess transcriptomic profiling of
[(Fig._3)TD$FIG]
Fig. 3. Multivariable correlates of HAI response: Geneset (Day 28 vs. Day 0). Results from the elastic
net logistic regression model for association of the genes in the “KUROZUMI” geneset with HAI
response. (A) The cross validated misclassification error rate (y-axis) as a function of the tuning
parameter (bottom x-axis) that governs the number of variables entered into the model (top x-axis). The
misclassification error rate indicates the portion of patients incorrectly classified. The error bars indicate
one standard error of the misclassification error rate. The vertical dashed lines indicate either the model
with the minimum cross validated error rate, or the model with cross validated error rate within one
standard error of the minimum rate. (B) The logistic regression coefficients for the genes selected in the
model with the minimum misclassification error. IFNG, IL10RA and CCR5 genes are positively
associated with influenza HAI response, whereas CCR9 gene is negatively associated with influenza
HAI response.
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influenza vaccine-induced humoral (HAI) response in older adults [20]. Both gene-
to-biology and biology-to-gene approaches were used to assess gene expression
and to characterize genesets in relation to influenza vaccine-induced humoral
antibody response. The gene-to-biology approach is an inductive, evidence-based
approach that utilizes individual per-gene variables. In contrast, the biology-to-
gene approach is an empirical approach that relies on known biological knowledge
to create genesets recognized to be involved in the immune response processes
[20]. Unlike our gene-to-biology approach, the latter analyses begin at the variable
set level and drill down to the per-variable level.
Our gene-to-biology per-gene analyses identified differentially expressed novel
and known genes related to influenza-specific HAI response. Since the FDR values
for these findings are large, we discuss them only briefly here. The majority of
transcriptomic changes related to positive HAI response were observed at Day 28
relative to baseline (the peak of adaptive humoral immune response mediated by
memory B cells). Twenty-two of the top 30 (73.3%) genes with significant (p <
0.01) transcriptional changes were found to be upregulated (Fig. 2A). The top two
genes differentially expressed in our study from Day 28 minus Day 0 are TGFBR1
(OR 2.72; p < 0.002) and the X chromosome-linked IFT52 genes (OR 2.78; p <
[(Fig._4)TD$FIG]
Fig. 4. Multivariable correlates of HAI response: Geneset (Day 28 vs. Day 3). Results from the elastic
net logistic regression model for association of the genes in the “STING” geneset with HAI response.
(A) The cross validated misclassification error rate (y-axis) as a function of the tuning parameter
(bottom x-axis) that governs the number of variables entered into the model (top x-axis). The
misclassification error rate indicates the portion of patients incorrectly classified. The error bars indicate
one standard error of the misclassification error rate. The vertical dashed lines indicate either the model
with the minimum cross validated error rate, or the model with cross validated error rate within one
standard error of the minimum rate. (B) The logistic regression coefficients for the genes selected from
the model that were selected from the model at the minimum misclassification error. ADAR, IRF1,
IRF7, and CCL5 genes are positively associated with influenza HAI response, whereas IRF6, IRF2, and
IRF9 genes are negatively associated with influenza HAI response.
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0.003). Notably, in our geneset (NOL7), the TGFBR1 gene also demonstrated a
positive association with HAI response (Table 2). TGFBR1 encodes a serine/
threonine protein kinase protein that transmits TGF-beta signal from the cell
surface into the cell, and is known to affect cell growth and division [44].
Likewise, we found several interesting genes related to HAI response, such as:
ZNF300 (zinc finger protein 300); NUP133 (nucleoporin 133 kDa); KLK1
(kallikrein 1); CD200 (CD200 membrane glycoprotein); and SLC9A3 (solute
carrier family 9, subfamily A) (all downregulated with the exception of HSPA14,
GPRIN1, GPR153). Conversely, the lowest number of significant gene expression
changes associated with influenza HAI response was observed at Day 28 relative to
Day 3 (top six genes) and at Day 3 relative to Day 0 (top six genes). These included
the cellular growth and division (helicase DDX28), cell cycle progression and
differentiation (S100A5), as well as regulation of NF-kappa-B-mediated transcrip-
tion (TONSL) genes and also genes with unknown function. The specific role of
these differentially expressed genes in influenza-induced adaptive immunity is
unclear. Hence, a gene expression replication study and a closer examination of
transcriptional activation induced by influenza vaccine are needed.
As a variety of genes and gene pathways are involved in influenza virus-induced
immune responses, we also used biology-to-gene analysis to identify genesets
associated with potential for explaining the variation in influenza-induced humoral
immunity inmultivariable models.We discuss these in greater depth here, as the FDR
values and cross-validation methods indicate these findings are more likely
reproducible than the gene-to-biology findings. This analysis is based on use of
gene sets, which has been shown to be both more powerful for detecting associations
and less susceptible to false discoveries [32, 45]. This analysis identified 13 genesets
(from existing public databases and the literature) with components (genes) related
both positively and negatively to the HAI response. Most of the specific genes
encompassing these genesets correspond to biological processes, including immune
regulation, inflammation, signal transduction, cell cycle and proliferation, and
biosynthesis (Table 2).We observed significant transcriptomic changes in genesets at
both timepoints: Day 28 vs. Day 0 and Day 28 vs. Day 3. Among eight genesets that
were identified at Day 28 vs. Day 0, are the five-gene (BAX, MAP2K4, MAPK3,
NSMAF, and TNFRSF1A) signatures (CERAMIDE) that contain genes that are
involved in processes such as P53-mediated apoptosis (BAX), proliferation,
differentiation, and transcription regulation (MAP2K4, MAPK3), as well as the
nuclear factor-kappa B signal transduction and tumor necrosis factor receptor
superfamily (TNFRSF)-induced cellular responses such as inflammation (NSMAF,
TNFRSF1A). Proteins encoded by the MAPKs (mitogen-activated protein kinases)
family and TNF genes have been shown to play an important role in directing innate
and adaptive (cytokine) immune responses and thus may influence influenza-specific
antibody response [46, 47]. Notably, one of the important genes in the “predictive
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Fig. 5. Interactions between genesets. A) Geneset interconnectivity, the fraction of genes between two
genesets that are regulatory partners, is illustrated. B) Geneset interconnectivity is shown for the 13
genesets identified with the lowest cross-validation error rate. While some gene sets are disjoint (share
no genes), many are not. Some share enough genes that we simply place an ‘X’ in the plot to indicate
that the sets are too similar for the metric to be meaningful. C) All genes in the 13 genesets (Table 2) are
shown in their network context. The extent of interconnectivity, quantified in panel B, is evident. The
majority of genes can be unambiguously colored by their inclusion in only 4 genesets. Edge type
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signatures” of neutralizing antibody responses to seasonal influenza vaccine and
yellow fever vaccine (YF-17D) in humans was the TNFRSF17 gene, which encodes
BCMA, a receptor for the B cell growth factor (BLyS-BAFF) [48, 49] and plays a
significant part in B cell differentiation and B cell homeostasis [19, 50]. In fact, the B
cell growth factor TNFRSF17 gene predicted the antibody response to YF-17D
vaccine with up to 100% accuracy [50].
Another interesting result is the identification of the gene signature (Day 28 vs. Day 0)
(KUROZUMI) related to variation in HAI titers. All genes comprising this specific
geneset (CCR5, CCR9, IFNG, and IL10RA) have an important known role in immune
function. Studies have also established that CCR5 expression is necessary for
influenza-specific CD8+ T cell response and for the clinical outcome of respiratory
influenza A virus infection [51, 52, 53]. A study of the trivalent 2004–2005 influenza
vaccine found that an age-related decrease in antibody response is inversely
correlated with high IL-10 secretion (p < 0.0001) [54]. The finding of these gene
signatures, with a possible relation to humoral antibody response following influenza
A/H1N1 vaccine, leads to the high possibility that these gene signatures may be
involved in influenza virus-induced immune activation and antibody response.
Our data comparing Day 28 vs. Day 3 identified multiple differentially expressed
genesets involved in immunity, cell migration and tissue remodeling, mRNA
processing, coagulation pathway, protein transport and glycolipid biosynthesis. An
important geneset signature (STING) was found in association with HAI response
(ADAR, CCL5, IRF1, IRF2, IRF6, IRF7, and IRF9). Specifically, molecules involved
in proliferation and activation of natural killer (NK) cells, such as chemotactic
cytokine CCL5 (RANTES), as well as transcriptional factors that control type I
interferons (IRF1, IRF2, IRF6, IRF7, IRF9), were significantly induced. Consistent
with this finding, a systems biology study of yellow fever vaccine (YF-17D) in
humans also found that expression of specific IRF genes is correlated with innate and
adaptive (antibody) response.
As systems biology approaches have shown promise in other studies, we linked
prioritized genesets together using known regulatory interactions to form a local
vaccine response network. Interestingly, of the 13 genesets highlighted, only four
are required to cover most of the genes involved. These four genesets (i.e., NOL7,
CERAMIDE, KUROZUMI, and STING) form a regulatory core with which
members of the remaining gene sets interact. The high degree of interconnectivity
between these genesets points to their related function, supporting the biology-to-
indicates the type of interaction. For clarity, at most one edge is shown between any two genes, with
transcription factor regulation (Trans Fac) taking the highest precedence, followed by chemical
modification (including phosphorylation), and other protein-protein interactions. Genes that are in a
geneset, but not detected by mRNA-seq in our samples are colored a lighter shade with darker border.
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gene paradigm. The integration of these diverse signaling processes into a common
regulatory model is a first step in identifying the dominant features involved in
determining the strength of response to influenza vaccination.
Our findings are in agreement with a report demonstrating that the 2008–2009
seasonal influenza vaccination upregulated gene expression of interferon-inducible
genes (IRF9, IFIT1, MX1) in the peripheral blood 24 hours after vaccination [55].
Nakaya et al. utilized a systems biology strategy to examine immune responses to
vaccination against TIV and live attenuated influenza vaccine (LAIV) [19]. This
study also identified the increased expression of interferon-associated genes after
vaccination with LAIV, such as IRF3 and IRF7 encoding proteins involved in
interferon signaling pathways [19]. In addition to IRF7 and IRF9, in our study we also
found that IRF1 is positively associated with HAI response, whereas IRF2 and IRF6
are negatively associated with influenza-specific HAI. Consistent with these
observations, Querec et al. examined early gene signatures that predict immune
responses following the attenuated live YF-17D vaccination [50]. Their results
indicated the verification of expression of several genes, including transcription
factors IRF7 and IRF9 induced by YF-17D vaccine [50]. The biological
understanding of these findings to vaccine-induced immune responses must be
further examined.
Li et al. also applied systems biology approaches to examine gene signatures of
antibody responses to five human vaccines [18]. They observed the IRF2 and
DDX58-like signaling genes were strongly correlated with carbohydrate-specific
antibody titers to the meningococcal quadrivalent polysaccharide (MPSV4) and
meningococcal polysaccharide-protein conjugate (MCV4) vaccines [18]. In our
geneset (STING), the IRF2 gene demonstrated a negative association with HAI
response (Fig. 4). IRF2 is known to inhibit IRF1-facilitated transcriptional
activation of IFN-α and IFN-β and other genes that use IRF1 for transcription
activation [56]. This suggests vaccines against influenza and the meningococcus
may use common genes, such as the IRF2, and different innate and adaptive
immune pathways to produce antibody responses [11, 18].
In our study, pre-existing immunity and the relationship of pre-existing HAI
antibodies with postvaccination antibody titers had an effect on the resulting
humoral response following influenza vaccine. It has been shown that the history
of an individual’s influenza vaccination likely influences his/her current response
to vaccine [57]. Our data are consistent with other studies demonstrating that high
baseline antibody titer inversely correlated with the postvaccination response to
influenza A/H1N1 vaccine [15, 57, 58].
Our gene expression results are based on PBMCs, which consist of multiple cell
types. We and others have observed small fold changes in mixed PBMCs [26,
27]. Geneset approaches are known to have higher power to detect changes in
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situations where there are many changes of small magnitude, such that they are
not readily detected by individual per-gene analyses.
The strengths of our study include the use of next generation sequencing, which
allows for whole transcriptome profiling, and the application of comprehensive
statistics and bioinformatics algorithms. Our study focuses on older individuals
(50–74 years of age), as signs of immunosenescence (increased susceptibility to
infection, vaccine failure) are frequently observed in this age group [59, 60, 61]. Our
analytical systems biology (gene-to-biology and biology-to-gene) approach allows us
to study transcriptional associations with HAI titers that are highly likely (based on
the literature and biologic plausibility) to explain variations in influenza A/H1N1-
induced humoral immune responses. We performed transcriptome profiling using a
heterogeneous cell population (PBMCs) without sequential isolation of neutrophils,
monocytes and T cell subsets. As the immune response to influenza A/H1N1 is a
complex interaction of different cells and mediators and is not controlled by a single
cell type, we assessed and found genesets associatedwith influenza HAI response in a
heterogeneous cell population. Our gene expression results are based on PBMCs,
which consist of multiple cell types. We and others have observed small fold changes
in mixed PBMCs [26, 27]. Geneset approaches are known to have higher power to
detect changes in situations where there are many changes of small magnitude, such
that they are not readily detected by individual per-gene analyses. Exploratory studies
of transcriptional profiling of isolated cell types from peripheral blood before and
after influenza vaccine are in progress.
A major strength of this analysis approach is that we utilized a priori information
from existing genesets that group genes based on biological rationale. Our
approach of filtering based on gene expression changes over time, in essence a
sophisticated variance filter we believe most likely to retain genes that are altered
consistently in response to vaccine, helps to control false discoveries since it was
agnostic to the outcome variable. In addition, the elastic net penalized regression
performs internal cross validation and shrinkage, which, in turn, should provide
more reproducible results, help reduce false discovery, and provide a realistic
measure of model performance. This resampling strategy for internal model
validation has several advantages over splitting the data into a discovery cohort
and replication cohort. Data splitting results in a costly reduction in sample size,
may provide different results if split differently, and does not validate the final
model fit to the full dataset. Cross validation avoids these disadvantages, and
therefore is a more efficient use of the data, and the generalizability of our
findings should be evaluated in an external cohort [38].
Despite these strategies that we employed tominimize false discoveries, due to a large
number of tests in our gene analysis, there is always the risk of false discoveries when
looking for potentially novel genes that impact immune response, and the
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generalizability of our findings should be evaluated in an external cohort. The
examination of gene expression in a control group of unvaccinated subjects would be
beneficial to this study. Theremight be a concern that antibody titers to the stalk of the
influenza hemagglutinin and other components of the TIV (influenza A/H3N2 and B
viruses) were not studied, and that possible sex-related differences in both influenza
HAI response and expression of genes (located on the X and Y chromosomes) were
not addressed in our study. We restricted our study to influenza A/H1N1 vaccine
since new influenza A/H1N1 strains represent a potentially devastating worldwide
public health threat, and because influenza A/California/7/2009/H1N1 virus is the A/
H1N1 component of the 2010–2011 trivalent vaccine when subjects were enrolled in
this study.
In summary, we have demonstrated that gene-to-biology and biology-to-gene
approaches can be applied to elucidate host genetic influences on the antibody
response to influenza vaccine. We identified a number of uncharacterized—and
confirmed previously reported—specific genes and genesets that displayed
associations with HAI response to seasonal influenza A/H1N1 vaccine. The
ability to detect gene signatures related to HAI response may assist with the design
of better vaccines and adjuvants to facilitate improved defenses against new strains
of influenza as emerging infectious agents. Future studies will attempt to unravel
the biological mechanisms underlying the involvement of a given gene/geneset, as
well as the function of the protein produced by that gene and its role in generating
immune responses.
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